Skip to main content

You are here:

LAPTOP (The Late Presenter Treatment Optimisation Study)

To compare two different types of HIV treatments, in terms of effectiveness and improvement of side effects, for patients who are diagnosed with a more advanced HIV infection.

An Open-Label, Multi-Centre, Randomized Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV-Disease

Key Eligibility Criteria

1. Ability to understand and sign a written informed consent form (ICF) and must be willing to comply with all study requirements

2. ≥ 18 years

3. HIV-1 infected AIDS except active tuberculosis (TB) or cryptococcal meningitis with any CD4 cell count, or; severe bacterial infection (BI) and must have a CD4 cell count < 200/µL within 28 days prior to study entry, or; any symptoms or no symptoms with CD4 cell count < 100/µL within 28 days prior to study entry and must have an entry HIV viral load > 1000 copies/mL, or; currently being treated for opportunistic infections (OI)

4. Have an entry HIV viral load > 1000 copies/mL

5. Able to take oral medications

6. ART-naïve prior to study enrolment

7. Willing to use acceptable methods of contraception

Therapeutic Area
Type of Study
Clinical trial PHASE IIIB
NEAT ID Foundation
Principal Investigator
Professor Paddy Mallon